A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

This study is testing whether adding canakinumab (an anti-inflammatory drug) and tislelizumab (an immunotherapy drug) to standard chemotherapy (nab-paclitaxel and gemcitabine) before surgery improves outcomes for people with resectable or borderline resectable pancreatic cancer. **You may be eligible if:** - You are 18 or older with a confirmed diagnosis of pancreatic ductal adenocarcinoma (a common type of pancreatic cancer) - Your tumor is confined to the pancreas and may be removable by surgery - You have not yet received any prior treatment for pancreatic cancer - Your general health is good (ECOG score 0–1) - Your organ function (blood counts, kidneys, liver) meets minimum requirements **You may NOT be eligible if:** - Your pancreatic cancer has spread beyond the pancreas to distant organs - You have active autoimmune disease or are on immunosuppressive therapy - You are pregnant or breastfeeding - You have serious infections or active inflammatory conditions Talk to your doctor to see if this trial is right for you.